Slowly but surely, Alzheimer's disease (AD) patients lose their memory and their cognitive
abilities, and even their personalities may change dramatically. These changes are due to …

A huge amount of evidence has implicated amyloid beta (Aβ) peptides and other derivatives
of the amyloid precursor protein (βAPP) as central to the pathogenesis of Alzheimer's …

Amyloid precursor protein (APP) is endoproteolytically processed by BACE1 and γ-
secretase to release amyloid peptides (Aβ40 and 42) that aggregate to form senile plaques …

Mutations in presenilins are the major cause of familial Alzheimer's disease, but the
pathogenic mechanism by which presenilin mutations cause memory loss and …

Abstract β-site APP cleaving enzyme 1 (BACE1) is the β-secretase enzyme required for
generating pathogenic β-amyloid (Aβ) peptides in Alzheimer's disease (AD). BACE1 …

Although many genetic disorders are characterized by cognitive failure during development,
there is little insight into the neurobiological basis for the abnormalities. Down syndrome …

Synaptic dysfunction and failure are processes that occur early in Alzheimer disease (AD)
and are important targets for protective treatments to slow AD progression and preserve …

The amyloid-β precursor protein is proteolytically cleaved by secretases, resulting in a series
of fragments, including the amyloid-β peptide of Alzheimer's disease. The amyloid precursor …

Cellular and molecular processes leading to abnormal accumulation of β amyloid in the
brain are slowly being uncovered. A potential involvement of insulin and insulin-like growth …

As the number of cases of Alzheimer's disease (AD) rises in all developed countries, the
unmet medical need for disease-modifying pharmacotherapy continues to grow. Much of AD …